AI platform for viral variant identification

Apriori Bio is at the forefront of developing innovative solutions to combat viral threats through its advanced technology platform, Octavia™. This platform leverages biology-enabled artificial intelligence to create comprehensive landscape maps of existing and potential viral variants. By analyzing how these variants interact with human cells and evade antibodies, Apriori Bio aims to identify the most significant threats posed by evolving viruses. This proactive approach allows the company to design variant-resilient vaccines that not only address current viral strains but also anticipate future outbreaks.

The Octavia™ platform employs a combination of cutting-edge techniques, including protein display systems, deep mutational scanning, single-cell sorting, and deep sequencing. These technologies enable Apriori Bio to isolate key protein fragments from target viruses and generate a vast array of non-replicating variant fragments. By measuring the interactions between these proteins and antibodies, the platform trains its AI to predict how potential variants might behave, ultimately guiding the development of vaccines that provide broad protection against a range of viral threats. This integrated approach positions Apriori Bio to enhance public health strategies and improve responses to viral outbreaks.

United States

Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants.  

Apriori was founded in 2020 in Flagship Labs, a unit of Flagship Pioneering. 

Apriori Bio

Company Details